Literature DB >> 27592118

Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study.

Davide Campana1, Davide Ravizza2, Piero Ferolla3, Antongiulio Faggiano4, Franco Grimaldi5, Manuela Albertelli6,7, Claudio Ricci8, Donatella Santini9, Nicole Brighi10, Nicola Fazio2, Annamaria Colao4, Diego Ferone6,7, Paola Tomassetti8.   

Abstract

The aim of this retrospective study was to evaluate the presence of risk factors for a type 1 gastric neuroendocrine neoplasia in a large cohort of patients with chronic atrophic gastritis. The study design consisted of an Italian multicentre, retrospective analysis. The study included all consecutive patients with chronic atrophic gastritis with or without type 1 gastric neuroendocrine neoplasias followed at the participating centres. Two hundred and twenty-nine patients with chronic atrophic gastritis were enroled at the participating centres. A total of 207 patients (154 female, 53 males, median age: 56.0 years) were included in the final analysis. One hundred and twenty-six patients had chronic atrophic gastritis without a gastric neuroendocrine neoplasia and 81 had a chronic atrophic gastritis with type 1 gastric neuroendocrine neoplasia. The median Chromogranin A level, evaluated in 141 patients, was 52.0 U/L. At upper gastrointestinal endoscopy, atrophy of the gastric mucosa was mild/moderate in 137 patients and severe in 68. Intestinal metaplasia of the corpus was present in 168 patients. At histological examination, 81 patients had a gastric neuroendocrine neoplasia (42 patients had a NET G1 and 33 a NET G2). The median Ki67 index was 2.0 %. At univariate and multivariate analysis, the risk factors for a gastric neuroendocrine neoplasia were: male gender, chromogranin A greater than 61 U/L, presence of intestinal metaplasia and age equal to or greater than 59 years. Chromogranin A greater than 61 U/L, the presence of intestinal metaplasia and male gender were independent risk factors for a type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis.

Entities:  

Keywords:  Chromogranin A; Chronic atrophic gastritis; Gastric carcinoid; Gastrin; Neuroendocrine tumours

Mesh:

Year:  2016        PMID: 27592118     DOI: 10.1007/s12020-016-1099-y

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  25 in total

1.  Development of type I gastric carcinoid in patients with chronic atrophic gastritis.

Authors:  L Vannella; A Sbrozzi-Vanni; E Lahner; C Bordi; E Pilozzi; V D Corleto; J F Osborn; G Delle Fave; B Annibale
Journal:  Aliment Pharmacol Ther       Date:  2011-04-15       Impact factor: 8.171

2.  Gastrin is the most important factor in ECL tumorigenesis.

Authors:  H L Waldum; A K Sandvik; J R Idle
Journal:  Gastroenterology       Date:  1998-05       Impact factor: 22.682

Review 3.  Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.

Authors:  Irvin M Modlin; Bjorn I Gustafsson; Steven F Moss; Marianne Pavel; Apostolos V Tsolakis; Mark Kidd
Journal:  Ann Surg Oncol       Date:  2010-03-09       Impact factor: 5.344

Review 4.  Review article: Pathogenesis and management of gastric carcinoid tumours.

Authors:  M D Burkitt; D M Pritchard
Journal:  Aliment Pharmacol Ther       Date:  2006-11-01       Impact factor: 8.171

Review 5.  Epidemiology of premalignant gastric lesions: implications for the development of screening and surveillance strategies.

Authors:  Annemarie C de Vries; Ernst J Kuipers
Journal:  Helicobacter       Date:  2007-11       Impact factor: 5.753

6.  Predictive value of gastrin levels for the diagnosis of gastric enterochromaffin-like cell hyperplasia in patients with Hashimoto's thyroiditis.

Authors:  Argyro Nicolaou; Dimitrios Thomas; Krystallenia I Alexandraki; Stavros Sougioultzis; Apostolos V Tsolakis; Gregory Kaltsas
Journal:  Neuroendocrinology       Date:  2014-04-24       Impact factor: 4.914

7.  Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids.

Authors:  M Peracchi; C Gebbia; G Basilisco; M Quatrini; C Tarantino; C Vescarelli; S Massironi; D Conte
Journal:  Eur J Endocrinol       Date:  2005-03       Impact factor: 6.664

Review 8.  Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994.

Authors:  M F Dixon; R M Genta; J H Yardley; P Correa
Journal:  Am J Surg Pathol       Date:  1996-10       Impact factor: 6.394

9.  Chromogranin A: is it a useful marker of neuroendocrine tumors?

Authors:  Davide Campana; Francesca Nori; Lidya Piscitelli; Antonio Maria Morselli-Labate; Raffaele Pezzilli; Roberto Corinaldesi; Paola Tomassetti
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  9 in total

Review 1.  How should incidental NEN of the pancreas and gastrointestinal tract be followed?

Authors:  Riccardo Ariotti; Stefano Partelli; Francesca Muffatti; Valentina Andreasi; Francesca Della Sala; Massimo Falconi
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

2.  Type I Gastric Neuroendocrine Tumor Presenting as Acute Upper Gastrointestinal Bleed.

Authors:  Anusha Bapatla; Ameena Syed; Abu Fazal Shaik Mohammed; Cortney V Jones; Rana Ismail
Journal:  Cureus       Date:  2021-05-31

Review 3.  Diagnosis and Management of Upper Gastrointestinal Neuroendocrine Tumors.

Authors:  Jun Liong Chin; Dermot O'Toole
Journal:  Clin Endosc       Date:  2017-11-30

4.  Gastric neuroendocrine neoplasms type 1: A systematic review and meta-analysis.

Authors:  Apostolos V Tsolakis; Athanasia Ragkousi; Miroslav Vujasinovic; Gregory Kaltsas; Kosmas Daskalakis
Journal:  World J Gastroenterol       Date:  2019-09-21       Impact factor: 5.742

5.  Gastric neuroendocrine neoplasias: manifestations and comparative outcomes.

Authors:  S Felder; H Jann; R Arsenic; T Denecke; V Prasad; B Knappe-Drzikova; S Maasberg; B Wiedenmann; M Pavel; A Pascher; U F Pape
Journal:  Endocr Relat Cancer       Date:  2019-09       Impact factor: 5.678

6.  A Prospective and Retrospective Clinical Controlled Observation of Chinese Herbal Decoction (SMLJ01) for Type 1 Gastric Neuroendocrine Tumors.

Authors:  Yingying Chen; Deng Han; Jiqing Zhu; Jie Chen; Haiyi Hu; Dou Dou; Xin Wang; Bing Yuan; Chao Wang; Zhirong Qi; Xinran Zhang; Jixi Liu; Jie Luo; Huangying Tan
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

Review 7.  Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use.

Authors:  Yoshikazu Kinoshita; Norihisa Ishimura; Shunji Ishihara
Journal:  J Neurogastroenterol Motil       Date:  2018-04-30       Impact factor: 4.924

Review 8.  Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome.

Authors:  Lingaku Lee; Irene Ramos-Alvarez; Tetsuhide Ito; Robert T Jensen
Journal:  Int J Mol Sci       Date:  2019-10-16       Impact factor: 5.923

9.  Metabolomic Study of Zuojin Pill in Relieving 1-Methyl-3-nitro-1-nitrosoguanidine-Induced Chronic Atrophic Gastritis.

Authors:  Yuling Tong; Manyi Jing; Xu Zhao; Honghong Liu; Shizhang Wei; Ruisheng Li; Xia Liu; Min Wang; Hongtao Song; Yanling Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-17       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.